--- title: "Ozempic May Be Changing More Than Appetite: a Question About Progesterone Absorption" entity: "blog" canonical_url: "https://www.drsmithnd.com/blog/ozempicandprogesteroneabsorption" markdown_url: "https://www.drsmithnd.com/llms/blog/ozempicandprogesteroneabsorption" lastmod: "2026-05-11T12:19:00.000Z" --- Sudden heavy bleeding in a menopause patient means I make room in my schedule relatively quickly. So recently when a long-time patient came in for a follow-up reporting five days of heavy bleeding, I asked a lot of questions, reviewed her medications, explained possible causes, and referred her for a prompt transvaginal pelvic ultrasound. Most commonly, postmenopausal bleeding is related to an imbalance in menopause hormone therapy, so that’s where we started: Did you change how you take your hormones or alter your dose? No. Any new medications? Major stressors? Bleeding triggered by intercourse? Vaginal discharge? No, no, no, and no. Did I have her on an appropriate dose of micronized progesterone to protect the uterine lining (from overgrowth caused by estrogen)? Yes — 200 mg. Was she on an excessive dose of estrogen? No. She had remained on 0.5 mg topical estradiol gel, which is actually a below-average dose. Fibroids, polyps, adenomyosis, cysts — all of these remain possible in menopause whether you are on hormone therapy or not. I know you’re thinking of the C word and you’re right to, because while cancer isn’t likely, it is still on the table. Postmenopausal bleeding can signal various gynecological cancers and most commonly endometrial cancer which is why these cases require timely investigation with imaging and sometimes an endometrial biopsy. Then I asked one more question. Any signs of high estrogen lately? Actually, yes. Breast tenderness, some irritability. Later that day I circled back and reviewed her chart again because something just did not sit right with me. Nobody develops significant endometrial overgrowth on that dose combination unless something else is happening. Then I saw it. Six months earlier, just before her previous follow-up, she had started Ozempic under the care of another doctor. My subsequent trip down the research rabbit hole turned up increasing discussion around GLP-1 medications potentially reducing the absorption of oral progesterone. What’s the big deal? Because progesterone protects the uterine lining. Without enough of it onboard, estrogen can stimulate the lining unchecked over time, increasing the risk of endometrial overgrowth and potentially cancer, that’s why it’s a big deal. GLP-1 medications work in part by slowing gastric emptying. Helpful metabolically, yes, but this may also alter how some oral medications are absorbed. Oral progesterone already has somewhat poor absorption, and delayed gastric emptying may make that even less reliable in some women. Of note, the population most frequently prescribed GLP-1 medications is already at a higher baseline risk for endometrial cancer. Obesity is a primary risk factor because adipose (fat) tissue acts as an active endocrine organ, producing and storing estrone. As GLP-1s trigger rapid weight loss, shrinking fat cells can cause fluctuations in circulating estrogen. When paired with delayed gastric emptying—which may interfere with the absorption of oral progesterone—this may create a period of unopposed estrogen. This hormonal imbalance is a documented driver of uterine thickening and requires careful clinical monitoring. So while my patient was taking her progesterone consistently, the question is whether she was adequately absorbing it. And ultimately, her ultrasound findings supported that concern. Her endometrial lining measured 6 mm - abnormal in a postmenopausal woman with bleeding and enough to warrant further investigation (endometrial biopsy, which was negative). That finding mattered because she was not on a high dose of estrogen nor too low a dose of progesterone. While one case does not prove causation, it raises an important clinical question about whether delayed gastric emptying from GLP-1 medications could reduce progesterone absorption enough to compromise endometrial protection in some women. Importantly, emerging evidence suggests GLP-1 receptor agonists may actually reduce overall endometrial cancer risk at a population level, very likely through improvements in obesity and metabolic health. C’est what? Well, as is often the case in life, both things can be true at the same time. GLP-1 medications may reduce overall risk through weight loss and improved metabolic health but while busy losing weight if progesterone absorption is compromised then the protective balance may be lost. What ...do we do with this conundrum? Well, we definitely do not freak out. We pay closer attention. We do not yet have strong long-term data guiding management in women using both GLP-1 medications and oral progesterone as part of menopause hormone therapy. The British Menopause Society however, has acknowledged the potential for altered oral progesterone absorption with GLP-1 agonists and recommends a lower threshold for investigation when bleeding occurs. This means considering strategies that bypass the gastrointestinal tract entirely such as a Mirena IUD, more frequent ultrasound monitoring, or sometimes vaginal progesterone, though the evidence confirming adequate endometrial protection with vaginal use remains limited. This is the job. It’s not about dramatic headlines or wild pendulum swings but careful pattern recognition, thoughtful observation, and researchers asking better questions about how therapies interact inside real human bodies. Warmly, Dr. Kirsten References - British Menopause Society. Progestogens and Endometrial Protection. British Menopause Society Tool for Clinicians, 2023. - The Menopause Society. Hormone Therapy Position Statement, 2022. - Endocrine Society. Clinical Practice Guideline on Treatment of Symptoms of the Menopause. - Postmenopausal Bleeding. American College of Obstetricians and Gynecologists Committee Opinion. - Crosbie EJ, et al. Obesity and endometrial cancer risk: mechanistic and epidemiological insights. Nature Reviews Endocrinology. - JAMA Network Open, 2026. Cohort study evaluating GLP-1 receptor agonist use and endometrial cancer risk. - Prescribing information for semaglutide notes delayed gastric emptying and potential impact on absorption of oral medications. Novo Nordisk #### Hi, I'm Dr. Kirsten Smith #### Women’s health warrior and advocate with 15+ years of experience in hormonal health My goal is to support women at all stages of their hormonal journey, through pre-perimenopause, perimenopause and post-menopause.